



PRODUCT: **Aimovig®**

COMPANY: Amgen

THERAPEUTIC AREA & INDICATION:

CGRP receptor blocker  
to treat chronic migraine

---

#### ABOUT THE PRODUCT

Following more than 30 years of research, in May 2018 Aimovig® (erenumab-aooe) became the first FDA-approved migraine preventive treatment designed to block the calcitonin gene-related peptide (CGRP) receptor, which is believed to play a critical role in migraine. A once-monthly injection, Aimovig has been studied in several clinical trials where it was proven to reduce monthly migraine days. Since its approval, more than 480,000 patients in the U.S. and an additional 500,000 patients around the world have been prescribed Aimovig for the preventive treatment of migraine in adults.